Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 237

1.

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.

Madsbad S.

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77. doi: 10.1016/j.beem.2009.03.008. Review.

PMID:
19748064
[PubMed - indexed for MEDLINE]
2.

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.

Pinelli NR, Hurren KM.

Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Review.

PMID:
21730278
[PubMed - indexed for MEDLINE]
3.

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

Drucker DJ, Nauck MA.

Lancet. 2006 Nov 11;368(9548):1696-705. Review.

PMID:
17098089
[PubMed - indexed for MEDLINE]
4.

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

Deacon CF, Mannucci E, Ahrén B.

Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24. Review.

PMID:
22471248
[PubMed - indexed for MEDLINE]
5.

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.

Tzefos M, Harris K, Brackett A.

Ann Pharmacother. 2012 Jan;46(1):68-78. doi: 10.1345/aph.1Q379. Review.

PMID:
22232377
[PubMed - indexed for MEDLINE]
6.

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ.

Diabetes Obes Metab. 2011 May;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x. Epub 2011 Jan 5. Review.

PMID:
21208359
[PubMed - indexed for MEDLINE]
7.

Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.

Gallwitz B.

Drugs. 2011 Sep 10;71(13):1675-88. doi: 10.2165/11592810-000000000-00000. Review.

PMID:
21902291
[PubMed - indexed for MEDLINE]
8.

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group.

Lancet. 2009 Jul 4;374(9683):39-47. doi: 10.1016/S0140-6736(09)60659-0. Epub 2009 Jun 8.

PMID:
19515413
[PubMed - indexed for MEDLINE]
9.

The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide.

Barnett AH.

Diabetes Obes Metab. 2012 Apr;14(4):304-14. doi: 10.1111/j.1463-1326.2011.01523.x. Epub 2011 Dec 22. Review.

PMID:
22051096
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Glucagon-like peptide analogues for type 2 diabetes mellitus.

Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD006423. doi: 10.1002/14651858.CD006423.pub2. Review.

PMID:
21975753
[PubMed - indexed for MEDLINE]
11.

GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.

Derosa G, Maffioli P.

Curr Clin Pharmacol. 2012 Aug;7(3):214-28. Review.

PMID:
22432846
[PubMed - indexed for MEDLINE]
12.

[Glucagon-like peptide 1 (GLP-1)].

Parhofer KG.

MMW Fortschr Med. 2007 Jun 21;149(25-26):41-3. German.

PMID:
17713050
[PubMed - indexed for MEDLINE]
13.

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.

Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL.

BMJ. 2012 Jan 10;344:d7771. doi: 10.1136/bmj.d7771. Review.

PMID:
22236411
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.

Verspohl EJ.

Pharmacol Ther. 2009 Oct;124(1):113-38. doi: 10.1016/j.pharmthera.2009.06.002. Epub 2009 Jun 21. Review.

PMID:
19545590
[PubMed - indexed for MEDLINE]
15.

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.

Madsbad S, Krarup T, Deacon CF, Holst JJ.

Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):491-9. doi: 10.1097/MCO.0b013e328302f414. Review.

PMID:
18542012
[PubMed - indexed for MEDLINE]
16.

Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.

Owens DR, Monnier L, Bolli GB.

Diabetes Metab. 2013 Dec;39(6):485-96. doi: 10.1016/j.diabet.2013.09.004. Epub 2013 Oct 22. Review.

PMID:
24156868
[PubMed - indexed for MEDLINE]
17.

GLP-1 receptor agonists: a clinical perspective on cardiovascular effects.

Mundil D, Cameron-Vendrig A, Husain M.

Diab Vasc Dis Res. 2012 Apr;9(2):95-108. doi: 10.1177/1479164112441526. Review.

PMID:
22496442
[PubMed - indexed for MEDLINE]
Free Article
18.

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.

Vergès B, Bonnard C, Renard E.

Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25. Review.

PMID:
21871831
[PubMed - indexed for MEDLINE]
Free Article
19.

Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.

Schnabel CA, Wintle M, Kolterman O.

Vasc Health Risk Manag. 2006;2(1):69-77. Review.

PMID:
17319471
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Emerging GLP-1 receptor agonists.

Lund A, Knop FK, Vilsbøll T.

Expert Opin Emerg Drugs. 2011 Dec;16(4):607-18. doi: 10.1517/14728214.2011.616493. Epub 2011 Sep 9. Review.

PMID:
21905764
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk